Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Центр психического здоровья, Беэр Шева, Израиль; Университет им. Бен Гуриона в Негеве, Беэр Шева, Израиль
Список исп. литературыСкрыть список 1. Manyam BV. Ayurvedic approach to neurologic illness. In: Alternative and Complementary Treatment in Neurologic Illness. M.I.Weintraub, M.S.Micozzi (eds). New York: Churchill Livingstone, 2001; p. 68–74. 2. Lang AE, Blair RDG. Anticholinergic drugs and amantadine in the treatment of Parkinson’s disease. In: Handbook of Experimental Pharmacology. Ed. D.B.Calne. Berlin, Heidelberg: Springer-Verlag, 1989; p. 307–23. 3. Anonimus. Management of Parkinson’s disease: an evidence-based review. Anticholinergic Therapies in the Treatment of Parkinson’s Disease. Mov Disord 2002; 17 (Suppl. 4): 7–12. 4. Goetz CG, Nausieda PA, Weiner WJ, Klawans HL. Practical guidelines for drug holidays in parkinsonian patients. Neurology 1981; 31: 641–2. 5. Horrocks PM, Vicary DJ, Rees JE et al. Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1973; 36: 936–41. 6. Яхно НН, Штульман ДР. Болезни нервной системы. М.: Медицина, 2001. 7. Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson’s disease. Clin Pharmacokinet 1996; 30: 463–81. 8. Tanner CM. Epidemiology of Parkinson's disease. Neurol Clin 1992; 10: 317–29. 9. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. American Academy of Neurology. Neurology 1998; 50: S1–57. 10. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Goodman and Gilman’s the Pharmacological Basis of Therapeutics. J.G.Hardman, L.E.Limbird, P.B.Molinoff, R.W.Ruddon, G.A.Goodman (eds). New York: McGraw-Hill, 1995; p. 503–19. 11. Sweeney PJ. Parkinson’s disease: managing symptoms and preserving function. Geriatrics 1995; 50: 24–31. 12. Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci 1999; 2: 39–46. 13. Strang RR. Clinical evaluation of biperiden in Parkinson’s disease. Dis Nerv Syst 1967; 28: 191–3. 14. Association AP. Diagnostic and Statistical Manual of Mental Disorders: DSM-5TM. 5th ed. Washington, DC: American Psychiatric Association, 2013; p. 712. 15. Van Putten T, Mutalipassi LR, Malkin MD. Phenothiazine-induced decompensation. Arch Gen Psychiatry 1974; 30: 102–5. 16. Baskak B, Atbasoglu EC, Ozguven HD et al. The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2007; 27: 289–94. 17. Friis T, Christensen TR, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatr Scand 1983; 67: 178–87. 18. Ayd FJ. Drug-induced extrapyramidal reactions: Their clinical manifestations and treatment with akineton. Psychosomatics 1960; 1: 2–8. 19. Medina C, Kramer MD, Kurland AA. Biperiden in the treatment of phenothiazine-induced extrapyramidal reactions. JAMA 1962; 182: 1127–9. 20. Eckmann F, Immich H. Neuroleptics and Dyskinetic Reactions. Nervenarzt 1963; 34: 374–6. 21. Kline NS, Mason BT, Winick L. Biperiden (Akineton): effective prophylactic and therapeutic anti-parkinsonian agent. Curr Ther Res Clin Exp 1974; 16: 838–43. 22. Hirose S, Ashby CR. Intravenous biperiden in akathisia: an open pilot study. Int J Psychiatry Med 2000; 30: 185–94. 23. Sachdev PS. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am 2005; 28: 255–74. 24. Povlsen UJ, Pakkenberg H. Effect of intravenous injection of biperiden and clonazepam in dystonia. Mov Disord 1990; 5: 27–31. 25. Левин O.C., Датиевa В.K. Применение биперидена (акинетона) у больных эфедроновой энцефалопатией. Журн. неврологии и психиатрии. 2013; 113: 33–7. 26. Konig P, Chwatal K, Havelec L et al. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996; 33: 80–4. 27. Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonian – and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995; 56: 167–70. 28. Soares KV, McGrath JJ. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000; CD000204. 29. Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry 1984; 145: 304–10. 30. Bhidayasiri R, Fahn S, Weiner WJ et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 81: 463–9. 31. Howland RH. The antidepressant effects of anticholinergic drugs. J Psychosoc Nurs Ment Health Serv 2009; 47: 17–20. 32. Kasper S, Moises HW, Beckmann H. The anticholinergic biperiden in depressive disorders. Pharmacopsychiatria 1981; 14: 195–8. 33. Gillin JC, Lauriello J, Kelsoe JR et al. No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial. Psychiatry Res 1995; 58: 99–105. 34. Beckmann H, Moises HW. The cholinolytic biperiden in depression. An acute placebo controlled study. Arch Psychiatr Nervenkr 1982; 231: 213–20. 35. Dimpfel W. Pharmacological modulation of cholinergic brain activity and its reflection in special EEG frequency ranges from various brain areas in the freely moving rat (Tele-Stereo-EEG). Eur Neuropsychopharmacol 2005; 15: 673–82. 36. Dimpfel W, Spuler M, Koch R, Schatton W. Radioelectroencephalographic comparison of memantine with receptor-specific drugs acting on dopaminergic transmission in freely moving rats. Neuropsychobiology 1987; 18: 212–8. 37. Myhrer T, Enger S, Aas P. Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman. Neurochem Res 2008; 33: 348–54. 38. Shih TM, McDonough JH. Efficacy of biperiden and atropine as anticonvulsant treatment for organophosphorus nerve agent intoxication. Arch Toxicol 2000; 74: 165–72. 39. Hodoba D, Schmidt D. Biperiden for treatment of somnambulism in adolescents and adults with or without epilepsy: clinical observations. Epilepsy Behav 2012; 25: 517–28. 40. Dose M, Tempel HD. Abuse potential of anticholinergics. Pharmacopsychiatry 2000; 33 (Suppl. 1): 43–6. 41. Buhrich N, Weller A, Kevans P. Misuse of anticholinergic drugs by people with serious mental illness. Psychiatr Serv 2000; 51: 928–9. 42. Hadidi KA. Development of a screening method for the most commonly abused anticholinergic drugs in Jordan; trihexyphenidyl, procyclidine and biperiden. Leg Med (Tokyo) 2004; 6: 233–41. 43. Schulte RM. Biperiden abuse as a partial factor in polytoxicomania. Psychiatr Prax 1988; 15: 53–6. 44. Espi Martinez F, Espi Forcen F, Shapov A, Martinez Moya A. Biperiden dependence: case report and literature review. Case Rep Psychiatry 2012; 949256. 45. Zacarias MS, Ramos AC, Alves DR, Galduroz JC. Biperiden (an M1-antagonist) reduces memory consolidation of cocaine-conditioned place preference. Neurosci Lett 2012; 513: 129–31. 46. Dieckmann LH, Ramos AC, Silva EA et al. Effects of biperiden on the treatment of cocaine/crack addiction: A randomised, double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2014. 47. Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 2003; 26: 233–42. 48. Terry AV Jr. Role of the central cholinergic system in the therapeutics of schizophrenia. Curr Neuropharmacol 2008; 6: 286–92. 49. Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol 2012; 26: 1167–74. 50. Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A Double-blind cross-over study. Br J Psychiatry 1995; 166: 241–3. 51. Ogino S, Miyamoto S, Tenjin T et al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 78–83. 52. Аведисова А.С., Бородин В.И., Чахова В.О. Акинетон или циклодол? Научно обоснованный терапевтический выбор. Психофармакология, 1998. 53. Liang CS, Ho PS, Shen LJ et al. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res 2010; 119: 138–44. 54. Kurlan R, Como P. Drug-induced alzheimerism. Arch Neurol 1988; 45: 356–7. 55. Vinogradov S, Fisher M, Warm H et al. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009; 166: 1055–62. 56. Okada T, Toichi M, Sakihama M. Influences of an anticholinergic antiparkinsonian drug, parkinsonism, and psychotic symptoms on cardiac autonomic function in schizophrenia. J Clin Psychopharmacol 2003; 23: 441–7. 57. Ikawa M, Tabuse H, Ueno S et al. Effects of combination psychotropic drug treatment on heart rate variability in psychiatric patients. Psychiatry Clin Neurosci 2001; 55: 341–5. 58. Kassa J. The influence of anticholinergic drug and oxime selection on the effectiveness of antidotal treatment against tabun-induced poisoning in mice. Acta Medica (Hradec Kralove) 2002; 45: 75–8. 59. Krejcova G, Kassa J. Anticholinergic drugs – functional antidotes for the treatment of tabun intoxication. Acta Medica (Hradec Kralove) 2004; 47: 13–8. 60. Hirose S. Insomnia related to biperiden withdrawal in two schizophrenic patients. Int Clin Psychopharmacol 2000; 15: 357–9. 61. Shinohara Y. Delirium caused by intramuscular administration of biperiden. J Neuropsychiatry Clin Neurosci 2010; 22: E15. 62. Wang LJ, Sun CL, Huang YL. Biperiden-induced delirium in an adolescent patient. J Child Adolesc Psychopharmacol 2011; 21: 499–500. 63. Richardson C, Kelly DL, Conley RR. Biperiden for excessive sweating from clozapine. Am J Psychiatry 2001; 158: 1329–30. 64. Акинетон. Инструкция по применению. URL: http://www. rlsnet.ru/tn_index_id_94.htm